Article Figures & Data
Tables
Administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq mCi mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 222 6 0.57 2.1 0.054 0.20 ↵* Adapted from ICRP 106 (37).
Weight-adjusted administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq/kg mCi/kg mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 3 0.08 0.79 2.9 0.071 0.26 * Adapted from ICRP 106 (37).
Weight-adjusted administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq/kg mCi/kg mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 3 0.08 1.8 6.7 0.16 0.59 * Adapted from ICRP 106 (37).
Stage of gestation mGy/MBq rad/mCi mGy rad Early 0.082 0.30 18 1.8 3 mo 0.060 0.22 13 0.13 6 mo 0.035 0.13 7.8 0.78 9 mo 0.031 0.11 6.9 0.69
Jump to section
- Article
- Abstract
- PREAMBLE
- I. INTRODUCTION
- II. GOALS
- III. DEFINITIONS
- IV. EXAMPLES OF CLINICAL AND RESEARCH INDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL (IN THE UNITED STATES)
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATION
- IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
- X. RADIATION SAFETY IN IMAGING
- XI. ISSUES REQUIRING FURTHER CLARIFICATION
- Acknowledgments
- XIV. APPROVAL
- Footnotes
- XIII. REFERENCES
- Figures & Data
- Info & Metrics